TRDA Entrada Therapeutics, Inc.

NASDAQ
$7.46

Entrada Therapeutics, Inc. (TRDA) is expected to report earnings on November 4, 2026, before the market open. The consensus earnings estimate is a loss of $0.98 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.1% since its last earnings release on August 5, 2026.

Entrada Therapeutics Beat Consensus Estimates
Wednesday, August 5, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 4
Wednesday · 7:10 AM ET
Earnings Whisper
-
vs ($0.98)
Rev est $10.3M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $7.12

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Entrada Therapeutics, Inc.

Entrada Therapeutics Inc. is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles(TM) to engage intracellular targets. Entrada Therapeutics Inc. is based in BOSTON.

Sector

Healthcare

Industry

Biotechnology